novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Overcoming the barriers of atherothrombotic risk – the challenge on the management of diabetic patients – Freek Verheugt

2 Agosto 2019

Resumo da Apresentação

Apresentação

Optimizing heart failure therapy from hospital to long-term treatment: the role of the heart failure network - José Ramón Juanatey

2 Agosto 2019
0

Polypill. A new strategy for prevention - Vivencio Barrios

2 Agosto 2019
0

-->